Neumora Therapeutics, INC. 8-K Filing
Ticker: NMRA · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $12.5 million, $2.5 million, $0.8774 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Neumora Therapeutics, INC. (ticker: NMRA) to the SEC on Nov 21, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ange on which registered Common Stock, $0.0001 par value per share NMRA The Nasdaq); $12.5 million (right to convert up to an aggregate of $12.5 million of the outstanding principal of the ter); $2.5 million (rsuant to which K2HV elected to convert $2.5 million of principal amount of the term loan in); $0.8774 (f the Company, at a conversion price of $0.8774 per share, in accordance with the Loan).
How long is this filing?
Neumora Therapeutics, INC.'s 8-K filing is 2 pages with approximately 569 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 569 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2025-11-21 16:05:18
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share NMRA The Nasdaq
- $12.5 million — right to convert up to an aggregate of $12.5 million of the outstanding principal of the ter
- $2.5 million — rsuant to which K2HV elected to convert $2.5 million of principal amount of the term loan in
- $0.8774 — f the Company, at a conversion price of $0.8774 per share, in accordance with the Loan
Filing Documents
- d873320d8k.htm (8-K) — 26KB
- 0001193125-25-291352.txt ( ) — 137KB
- nmra-20251117.xsd (EX-101.SCH) — 3KB
- nmra-20251117_lab.xml (EX-101.LAB) — 18KB
- nmra-20251117_pre.xml (EX-101.PRE) — 11KB
- d873320d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUMORA THERAPEUTICS, INC. Date: November 21, 2025 By: /s/ Michael Milligan Michael Milligan Chief Financial Officer